Selinexor: Changing the paradigm in patients with TP53 wild-type endometrial cancer?

Mohamed A. Gouda; Kyaw Z. Thein

doi:10.1016/j.medj.2023.10.005

Selinexor: Changing the paradigm in patients with TP53 wild-type endometrial cancer?

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Recurrent endometrial cancer (EC) remains a therapeutic challenge despite advancements in personalized medicine. SIENDO trial showed the potential clinical benefit of selinexor in patients with TP53 wild-type advanced/recurrent EC. The quest for novel therapeutic avenues and approaches continues as researchers seek a glimmer of hope in an area of uncertainty.

Original language	English (US)
Pages (from-to)	752-754
Number of pages	3
Journal	Med
Volume	4
Issue number	11
DOIs	https://doi.org/10.1016/j.medj.2023.10.005
State	Published - Nov 10 2023
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.medj.2023.10.005

Cite this

@article{a3b92a647bc0492c9e6d48dcd6b21e71,

title = "Selinexor: Changing the paradigm in patients with TP53 wild-type endometrial cancer?",

abstract = "Recurrent endometrial cancer (EC) remains a therapeutic challenge despite advancements in personalized medicine. SIENDO trial showed the potential clinical benefit of selinexor in patients with TP53 wild-type advanced/recurrent EC. The quest for novel therapeutic avenues and approaches continues as researchers seek a glimmer of hope in an area of uncertainty.",

author = "Gouda, {Mohamed A.} and Thein, {Kyaw Z.}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = nov,

day = "10",

doi = "10.1016/j.medj.2023.10.005",

language = "English (US)",

volume = "4",

pages = "752--754",

journal = "Med",

issn = "2666-6359",

publisher = "Cell Press",

number = "11",

}

TY - JOUR

T1 - Selinexor

T2 - Changing the paradigm in patients with TP53 wild-type endometrial cancer?

AU - Gouda, Mohamed A.

AU - Thein, Kyaw Z.

PY - 2023/11/10

Y1 - 2023/11/10

N2 - Recurrent endometrial cancer (EC) remains a therapeutic challenge despite advancements in personalized medicine. SIENDO trial showed the potential clinical benefit of selinexor in patients with TP53 wild-type advanced/recurrent EC. The quest for novel therapeutic avenues and approaches continues as researchers seek a glimmer of hope in an area of uncertainty.

AB - Recurrent endometrial cancer (EC) remains a therapeutic challenge despite advancements in personalized medicine. SIENDO trial showed the potential clinical benefit of selinexor in patients with TP53 wild-type advanced/recurrent EC. The quest for novel therapeutic avenues and approaches continues as researchers seek a glimmer of hope in an area of uncertainty.

UR - http://www.scopus.com/inward/record.url?scp=85175705631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85175705631&partnerID=8YFLogxK

U2 - 10.1016/j.medj.2023.10.005

DO - 10.1016/j.medj.2023.10.005

M3 - Comment/debate

C2 - 37951208

AN - SCOPUS:85175705631

SN - 2666-6359

VL - 4

SP - 752

EP - 754

JO - Med

JF - Med

IS - 11

ER -

Selinexor: Changing the paradigm in patients with TP53 wild-type endometrial cancer?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this